SLAM
MDGL icon

Swiss Life Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Swiss Life Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$557K Buy
1,037
+107
+12% +$54.8K ﹤0.01% 905
2026
Q1 		$487K Buy
930
+240
+35% +$115K ﹤0.01% 877
2025
Q4 		$402K Buy
690
+44
+7% +$22.5K ﹤0.01% 883
2025
Q3 		$296K Buy
+646
New +$241K ﹤0.01% 918

Other funds holding MDGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Swiss Life Asset Management's MDGL Position: Q2 2026 in Review

Swiss Life Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 12% in Q2 2026, buying an estimated $54.8K and bringing the position to 1,037 shares worth $557K. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Swiss Life Asset Management first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Swiss Life Asset Management held 1,037 shares of Madrigal Pharmaceuticals worth $557K as of Q2 2026.
  • Swiss Life Asset Management bought 107 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $54.8K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #905 holding.
  • Swiss Life Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.